EDAP Announces Letter of Intent for 36 Million Euro Credit Facility to Accelerate Growth and Strategic Expansion
EDAP TMS SA (Nasdaq: EDAP), a leader in robotic energy-based therapies, has secured a letter of intent for a €36 million credit facility from the European Investment Bank (EIB). The financing will support the expansion of Focal One® Robotic HIFU technology for early-stage prostate cancer treatment and accelerate development of new clinical indications.
The credit facility, expected to close by the end of 2025, will provide low-interest funding accessible in tranches. CEO Ryan Rhodes highlighted that this strategic financing will strengthen EDAP's balance sheet and help expand access to Focal One Robotic HIFU technology for physicians and patients.
EDAP TMS SA (Nasdaq: EDAP), azienda leader nelle terapie robotiche a base di energia, ha ottenuto una lettera d'intenti per una linea di credito da €36 milioni dalla Banca Europea per gli Investimenti (BEI). Il finanziamento sosterrà l'espansione della tecnologia Focal One® Robotic HIFU per il trattamento del cancro alla prostata in fase iniziale e accelererà lo sviluppo di nuove indicazioni cliniche.
La linea di credito, che si prevede sarà perfezionata entro la fine del 2025, fornirà fondi a tasso agevolato erogati per tranche. L'amministratore delegato Ryan Rhodes ha sottolineato che questo finanziamento strategico rafforzerà il bilancio di EDAP e faciliterà l'accesso alla tecnologia Focal One Robotic HIFU per medici e pazienti.
EDAP TMS SA (Nasdaq: EDAP), líder en terapias robóticas basadas en energía, ha obtenido una carta de intenciones para una línea de crédito de €36 millones del Banco Europeo de Inversiones (BEI). La financiación apoyará la expansión de la tecnología Focal One® Robotic HIFU para el tratamiento del cáncer de próstata en estadios tempranos y acelerará el desarrollo de nuevas indicaciones clínicas.
La línea de crédito, que se espera cerrar antes de finales de 2025, ofrecerá fondos a bajo interés disponibles en tramos. El director ejecutivo Ryan Rhodes destacó que esta financiación estratégica fortalecerá el balance de EDAP y ayudará a ampliar el acceso a la tecnología Focal One Robotic HIFU para médicos y pacientes.
EDAP TMS SA (Nasdaq: EDAP), 에너지 기반 로봇 치료 분야의 선두기업이 유럽투자은행(EIB)으로부터 3600만 유로 신용공여 약정서를 확보했습니다. 이번 자금은 초기 전립선암 치료용 Focal One® 로보틱 HIFU 기술의 확장과 새로운 임상 적응증 개발 가속화를 지원할 예정입니다.
이 신용공여는 2025년 말까지 마무리될 것으로 예상되며, 저금리 자금이 분할로 제공됩니다. CEO 라이언 로즈(Ryan Rhodes)는 이번 전략적 자금조달이 EDAP의 재무구조를 강화하고 의료진과 환자들의 Focal One Robotic HIFU 기술 접근성을 확대하는 데 기여할 것이라고 강조했습니다.
EDAP TMS SA (Nasdaq: EDAP), leader des thérapies robotiques utilisant l'énergie, a obtenu une lettre d'intention pour une facilité de crédit de 36 M€ auprès de la Banque européenne d'investissement (BEI). Ce financement soutiendra le déploiement de la technologie Focal One® Robotic HIFU pour le traitement du cancer de la prostate à un stade précoce et accélérera le développement de nouvelles indications cliniques.
La facilité de crédit, dont la clôture est prévue d'ici fin 2025, fournira des fonds à faible taux d'intérêt disponibles par tranches. Le directeur général Ryan Rhodes a souligné que ce financement stratégique renforcera le bilan d'EDAP et contribuera à élargir l'accès des médecins et des patients à la technologie Focal One Robotic HIFU.
EDAP TMS SA (Nasdaq: EDAP), ein führendes Unternehmen für energiegestützte Robotiktherapien, hat eine Absichtserklärung für eine €36 Millionen Kreditfazilität von der Europäischen Investitionsbank (EIB) erhalten. Die Finanzierung wird die Verbreitung der Focal One® Robotic HIFU-Technologie zur Behandlung von Prostatakrebs im Frühstadium unterstützen und die Entwicklung neuer klinischer Indikationen beschleunigen.
Die Kreditfazilität, deren Abschluss bis Ende 2025 erwartet wird, stellt zinsgünstige Mittel bereit, die in Tranchen abrufbar sind. CEO Ryan Rhodes betonte, dass diese strategische Finanzierung die Bilanz von EDAP stärken und den Zugang von Ärzten und Patienten zur Focal One Robotic HIFU-Technologie erweitern werde.
- Secured €36 million credit facility with favorable low-interest terms
- Funding can be accessed flexibly in tranches as needed
- Strategic partnership with European Investment Bank enhances credibility
- Capital will support expansion of Focal One® Robotic HIFU technology
- Strengthens balance sheet for growth initiatives
- Credit facility is still subject to final legal documentation
- Additional debt could increase financial obligations
Funding to Support Continued Growth of Focal One® Robotic HIFU
AUSTIN, Texas, August 26, 2025 - EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced execution of a letter of intent for EUR 36 million credit facility with the European Investment Bank (EIB). Proceeds from this financing will support the continued expansion of Focal One® Robotic HIFU in Focal Therapy, the fastest-growing treatment category for early-stage prostate cancer while accelerating the development of new clinical indications. Pending the signature of the final legal documents, the Credit Facility is expected to close no later than the end of Calendar Year 2025.
“We are pleased to announce this agreement on a letter of intent for such an important and strategic financing facility with the European Investment Bank,” said Ryan Rhodes, Chief Executive Officer of EDAP. "The capital raised through this financing immediately enhances our balance sheet, offering a substantial source of low-interest funding that we can access in tranches as needed." Over the last several years, the EIB has been an extraordinary partner in helping companies deliver new and promising innovative technologies for the benefit of millions of patients across the globe. I would like to thank the EIB for their support, as we believe this additional capital will enable more physicians and their patients to access the benefits of Focal One Robotic HIFU.”
About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes, and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as “believe,” “can,” “contemplate,” “could,” “plan,” “intend,” “is designed to,” “may,” “might,” “potential,” “objective,” “target,” “project,” “predict,” “forecast,” “ambition,” “guideline,” “should,” “will,” “estimate,” “expect” and “anticipate,” or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements include our expectations to enter into a credit facility with EIB, the size thereof, the timing thereof and the use of proceeds from such credit facility. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services. Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com
FAQ
What is the size of EDAP's new credit facility with European Investment Bank?
When will EDAP's credit facility with EIB close?
How will EDAP use the funds from the EIB credit facility?
What are the terms of EDAP's EIB credit facility?
How will the EIB credit facility benefit EDAP's growth strategy?
